Synairgen’s SNG001 is a nebulizer containing interferon beta-1a that showed great promise in a recent Phase 2 trial. Volunteers who received the drug had greater odds of recovering from COVID-19 than placebo controls. >>
Synairgen’s SNG001 is a nebulizer containing interferon beta-1a that showed great promise in a recent Phase 2 trial. Volunteers who received the drug had greater odds of recovering from COVID-19 than placebo controls. >>
The researchers who developed an interferon nebulizer for coronavirus patients have published promising results for a Phase 2 trial. The Synairgen SNG001 nebulizer helped hospitalized patients recover from COVID-19 faster than a group >>